Replies to post #12850 on Biotech Values

[DewDiligence]

>>The HR [Hazard Ratio] for Provenge is indeed moderately groundshaking for a cancer treatment and it primarily shows up in the out years.<<

Agreed—that and the low valuation are the reasons I’m long in spite of all the “warts.”